Loading clinical trials...
Loading clinical trials...
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) and Evaporative Dry Eye Disease (DED)
Conditions
Interventions
AZR-MD-001 Low Dose
AZR-MD-001 Mid Dose
+2 more
Locations
30
Australia
Vision Eye Institute
Chatswood, New South Wales, Australia
Eye Associates
Sydney, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
School of Optometry and Vision Science, University of New South Wales
Sydney, New South Wales, Australia
Queensland University of Technology
Brisbane, Queensland, Australia
Queensland Eye Institute
South Brisbane, Queensland, Australia
Start Date
September 10, 2018
Primary Completion Date
September 14, 2022
Completion Date
October 19, 2022
Last Updated
February 28, 2024
NCT07463950
NCT07363824
NCT07396441
NCT05865457
NCT05865379
NCT07366944
Lead Sponsor
Azura Ophthalmics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions